Pathogen reduction for DoD
This article was originally published in The Gray Sheet
Executive Summary
Navigant Biotechnologies receives $2 mil. from the U.S. Department of Defense for development of Mirasol riboflavin-based pathogen reduction technology for red blood cells. The funding was included in DoD's 2004 $317.2 bil. budget, signed Sept. 30. Walter Reed Army Institute of Research will participate in development of Mirasol, which is slated to enter Phase I trials in early 2004 (1"The Gray Sheet" Sept. 8, 2003, p. 14)...